Logo image of ALTS

ALT5 SIGMA CORP (ALTS) Stock Fundamental Analysis

NASDAQ:ALTS - Nasdaq - US47089W1045 - Common Stock - Currency: USD

8.23  +0.35 (+4.44%)

After market: 8.23 0 (0%)

Fundamental Rating

2

Taking everything into account, ALTS scores 2 out of 10 in our fundamental rating. ALTS was compared to 195 industry peers in the Pharmaceuticals industry. ALTS has a bad profitability rating. Also its financial health evaluation is rather negative. ALTS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ALTS had negative earnings in the past year.
In the past year ALTS had a positive cash flow from operations.
ALTS had negative earnings in 4 of the past 5 years.
In multiple years ALTS reported negative operating cash flow during the last 5 years.
ALTS Yearly Net Income VS EBIT VS OCF VS FCFALTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

1.2 Ratios

With a decent Return On Assets value of -8.92%, ALTS is doing good in the industry, outperforming 70.77% of the companies in the same industry.
With a decent Return On Equity value of -27.10%, ALTS is doing good in the industry, outperforming 66.15% of the companies in the same industry.
Industry RankSector Rank
ROA -8.92%
ROE -27.1%
ROIC N/A
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALTS Yearly ROA, ROE, ROICALTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

Looking at the Gross Margin, with a value of 49.24%, ALTS is in the better half of the industry, outperforming 62.56% of the companies in the same industry.
In the last couple of years the Gross Margin of ALTS has grown nicely.
The Profit Margin and Operating Margin are not available for ALTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
ALTS Yearly Profit, Operating, Gross MarginsALTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

1

2. Health

2.1 Basic Checks

ALTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALTS has more shares outstanding
The number of shares outstanding for ALTS has been increased compared to 5 years ago.
Compared to 1 year ago, ALTS has a worse debt to assets ratio.
ALTS Yearly Shares OutstandingALTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ALTS Yearly Total Debt VS Total AssetsALTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 0.37, we must say that ALTS is in the distress zone and has some risk of bankruptcy.
ALTS's Altman-Z score of 0.37 is in line compared to the rest of the industry. ALTS outperforms 55.38% of its industry peers.
The Debt to FCF ratio of ALTS is 18.18, which is on the high side as it means it would take ALTS, 18.18 years of fcf income to pay off all of its debts.
ALTS's Debt to FCF ratio of 18.18 is fine compared to the rest of the industry. ALTS outperforms 78.46% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that ALTS is somewhat dependend on debt financing.
ALTS has a worse Debt to Equity ratio (0.55) than 62.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 18.18
Altman-Z 0.37
ROIC/WACCN/A
WACC9.66%
ALTS Yearly LT Debt VS Equity VS FCFALTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 0.83 indicates that ALTS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.83, ALTS is doing worse than 87.69% of the companies in the same industry.
A Quick Ratio of 0.83 indicates that ALTS may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.83, ALTS is doing worse than 82.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.83
ALTS Yearly Current Assets VS Current LiabilitesALTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.79% over the past year.
Measured over the past years, ALTS shows a very negative growth in Revenue. The Revenue has been decreasing by -18.62% on average per year.
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.87%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALTS will show a very strong growth in Earnings Per Share. The EPS will grow by 32.10% on average per year.
ALTS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 65.13% yearly.
EPS Next Y7.14%
EPS Next 2Y32.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year185.91%
Revenue Next 2Y117.15%
Revenue Next 3Y79.76%
Revenue Next 5Y65.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALTS Yearly Revenue VS EstimatesALTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
ALTS Yearly EPS VS EstimatesALTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALTS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALTS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALTS Price Earnings VS Forward Price EarningsALTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ALTS is valued a bit cheaper than 77.44% of the companies in the same industry.
Industry RankSector Rank
P/FCF 184.59
EV/EBITDA N/A
ALTS Per share dataALTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

ALTS's earnings are expected to grow with 32.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.1%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

ALTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALT5 SIGMA CORP

NASDAQ:ALTS (7/3/2025, 8:27:21 PM)

After market: 8.23 0 (0%)

8.23

+0.35 (+4.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01
Earnings (Next)08-18 2025-08-18
Inst Owners7.89%
Inst Owner Change0%
Ins Owners4.19%
Ins Owner Change0%
Market Cap143.61M
Analysts0
Price TargetN/A
Short Float %4.17%
Short Ratio2.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.96
P/FCF 184.59
P/OCF 184.59
P/B 5.59
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)0.04
FCFY0.54%
OCF(TTM)0.04
OCFY0.54%
SpS1.03
BVpS1.47
TBVpS-1.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.92%
ROE -27.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.24%
FCFM 4.31%
ROA(3y)-8.77%
ROA(5y)-34.52%
ROE(3y)-9.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y31.18%
GM growth 5Y17.71%
F-Score5
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 18.18
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.83
Altman-Z 0.37
F-Score5
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.87%
EPS Next Y7.14%
EPS Next 2Y32.1%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-32.08%
Revenue growth 5Y-18.62%
Sales Q2Q%N/A
Revenue Next Year185.91%
Revenue Next 2Y117.15%
Revenue Next 3Y79.76%
Revenue Next 5Y65.13%
EBIT growth 1Y-45.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.41%
EBIT Next 3Y44.5%
EBIT Next 5Y44.66%
FCF growth 1Y119.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y128.92%
OCF growth 3YN/A
OCF growth 5YN/A